Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Boron neutron capture therapy shows promise for deadly brain tumors

Boron neutron capture therapy shows promise for deadly brain tumors

Armored CAR T cells overcome tumor defenses in solid cancers

Armored CAR T cells overcome tumor defenses in solid cancers

HIT cell therapy eradicates solid tumors in preclinical models

HIT cell therapy eradicates solid tumors in preclinical models

Innovative laser procedure offers new hope for recurrent brain tumors

Innovative laser procedure offers new hope for recurrent brain tumors

Phase 2 clinical trial tests LMP744 for the treatment of first-time recurrent glioblastoma

Phase 2 clinical trial tests LMP744 for the treatment of first-time recurrent glioblastoma

Niacin shows promise in improving treatment for glioblastoma patients

Niacin shows promise in improving treatment for glioblastoma patients

Chronic brain compression triggers neuron death through multiple pathways

Chronic brain compression triggers neuron death through multiple pathways

Bioadhesive patches target remaining glioblastoma cells after surgery

Bioadhesive patches target remaining glioblastoma cells after surgery

Triple negative breast cancer cells use new strategy to boost metastatic ability

Triple negative breast cancer cells use new strategy to boost metastatic ability

Small molecule targets glioblastoma oncogene in preclinical studies

Small molecule targets glioblastoma oncogene in preclinical studies

Ride Cincinnati grant funds research on immune activating wafer for glioblastoma treatment

Ride Cincinnati grant funds research on immune activating wafer for glioblastoma treatment

Researchers open ‘window to the brain’ with powerful cancer tech

Researchers open ‘window to the brain’ with powerful cancer tech

Researchers identify key factor to help improve treatment for glioblastoma

Researchers identify key factor to help improve treatment for glioblastoma

Brain organoids reveal glioblastoma's secrets and therapy resistance

Brain organoids reveal glioblastoma's secrets and therapy resistance

Cancer vaccines enter a new era of personalized immunotherapy

Cancer vaccines enter a new era of personalized immunotherapy

Digital twin technology guides personalized treatment for brain cancer patients

Digital twin technology guides personalized treatment for brain cancer patients

Unveiling IDH-mutant glioma's roots: A new path for early diagnosis

Unveiling IDH-mutant glioma's roots: A new path for early diagnosis

Novel approach uncovers possible drugs based on specific cellular targets for treating glioblastoma

Novel approach uncovers possible drugs based on specific cellular targets for treating glioblastoma

New breakthrough could modernize treatment for glioblastoma

New breakthrough could modernize treatment for glioblastoma

New diagnostic chip enables rapid monitoring of brain cancer treatment

New diagnostic chip enables rapid monitoring of brain cancer treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.